卢修斯制药LuciSelin 塞利尼索 Selinexor

• In combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
• In combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
• For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, who have received at least two lines of systemic therapy.

Dosage and Administration

• Multiple Myeloma in combination with bortezomib and dexamethasone (XVd regimen): Recommended dose is 100 mg orally once weekly.
• Multiple Myeloma in combination with dexamethasone (Xd regimen): Recommended dose is 80 mg orally on Day 1 and Day 3 of each week.
• Diffuse Large B-Cell Lymphoma (DLBCL): Recommended dose is 60 mg orally on Day 1 and Day 3 of each week.

Specification
20 mg per tablet, 32 tablets per box.